Comparative Pharmacology
Head-to-head clinical analysis: HYDROXYCHLOROQUINE versus KRINTAFEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROXYCHLOROQUINE versus KRINTAFEL.
Hydroxychloroquine vs KRINTAFEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydroxychloroquine is a 4-aminoquinoline antimalarial agent that accumulates in lysosomes and inhibits Toll-like receptor signaling, reduces cytokine production, and interferes with antigen presentation. It also inhibits heme polymerase in malarial parasites, leading to toxic heme accumulation.
KRINTAFEL (tafenoquine) is an 8-aminoquinoline antimalarial that inhibits parasite growth by interfering with the electron transport chain in the mitochondria of Plasmodium species. It is active against both the erythrocytic and exoerythrocytic stages, including hypnozoites of P. vivax.
400 mg orally once daily or 200 mg orally twice daily, then 200-400 mg orally once daily for maintenance, depending on indication.
Adults: 200 mg orally as a single dose.
None Documented
None Documented
Clinical Note
moderateHydroxychloroquine + Fesoterodine
"The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Hydroxychloroquine."
Clinical Note
moderateHydroxychloroquine + Artemether
"The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Artemether."
Clinical Note
moderateHydroxychloroquine + Chloroquine
"The serum concentration of Chloroquine can be decreased when it is combined with Hydroxychloroquine."
Clinical Note
moderateTerminal half-life: 30-60 days (prolonged due to extensive tissue binding); clinical context: requires loading dose for rapid effect.
Terminal elimination half-life is approximately 5-7 days in healthy subjects. Due to accumulation, steady state is achieved after 4-5 weeks of weekly dosing. In patients with renal impairment, half-life may be prolonged.
Primarily renal (30-60% unchanged); minor hepatic metabolism; fecal elimination accounts for ~20-30%.
Primarily renal; approximately 70-80% of administered dose is excreted unchanged in urine via glomerular filtration and active tubular secretion. Fecal excretion accounts for less than 5%.
Category A/B
Category C
Antimalarial / DMARD
Antimalarial
Hydroxychloroquine + Lumefantrine
"The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Lumefantrine."